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Abstract
Glioblastoma (GBM) is the most prevalent adult brain tumor, with virtually no cure, and with
a median overall survival of 15 months from diagnosis despite of the treatment. SNARE pro-
teins mediate membrane fusion events in cells and are essential for many cellular process-
es including exocytosis and neurotransmission, intracellular trafficking and cell migration.
Here we show that the blockade of the SNARE protein Syntaxin 1 (Stx1) function impairs
GBM cell proliferation. We show that Stx1 loss-of-function in GBM cells, through ShRNA
lentiviral transduction, a Stx1 dominant negative and botulinum toxins, dramatically reduces
the growth of GBM after grafting U373 cells into the brain of immune compromised mice. In-
terestingly, Stx1 role on GBM progression may not be restricted just to cell proliferation
since the blockade of Stx1 also reduces in vitroGBM cell invasiveness suggesting a role in
several processes relevant for tumor progression. Altogether, our findings indicate that the
blockade of SNARE proteins may represent a novel therapeutic tool against GBM.
Introduction
Glioblastoma is the most common type of primary brain tumor in adults. Despite significant
advances in the understanding of the molecular and cellular basis of tumor origin and progres-
sion, GBM is usually fatal, with a median overall survival of 15 months from diagnosis despite
of the treatment [1,2]. SNARE proteins are essential for many cellular events requiring mem-
brane fusion, including exocytosis and neurotransmission, intracellular trafficking, and cell
proliferation [3,4]. They have been classically divided in two groups: t-SNAREs (including syn-
taxin and SNAP family proteins) and v-SNAREs (including Vamp family proteins), depending
on whether they are located at the target membrane or the donor vesicle respectively. In the
nervous system, the t-SNAREs SNAP25 and Stx1 and the v-SNARE VAMP2 are required for
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calcium-dependent exocytosis and neurotransmitter release [5]. Recent findings have implicat-
ed several SNARE proteins, particularly Stx1, in axonal growth and neuronal migration [6,7,8].
Two main Stx1 isoforms have been recognized (Stx1a and Stx1b) which display a differentiated
pattern of expression [9]. Interestingly, Stx1 is expressed in several tumors, including small cell
lung carcinoma and the most aggressive forms of colorectal cancer [10,11]. Given that SNARE
proteins are involved in neuronal migration and GBM is a very invasive tumor, here we exam-
ined whether the blockade of the exocytotic machinery, in particular Stx1 inactivation, has an
impact on the growth and progression of GBM in vivo.
Material and Methods
Cells
GBMU251, C52, C4, hs683, T98G, A172, U87 and U373 cells were obtained from ATCC. All
the cells were cultured in DMEM supplemented with 10% FBS at 37°C and 5% CO2. GFP and
the rat Stx1a H3TM domain fused with EGFP cloned into a pEGP vector [7] were transiently
transfected by using the Neon Transfection System (Invitrogen) according to the manufactur-
er’s instructions. To establish U373 populations stably expressing a GFP-firefly luciferase fu-
sion protein, cells distributed in six 10 cm dishes were transfected with pEGFP-Luc vector
(Promega) using the Lipofectamine Plus system (Invitrogen) and following the manufacture’s
instructions. Cells were then selected in normal media supplemented with 500 ug/ml G418 and
positive GFP cells were isolated from the surviving cells by two rounds of FACS. U373 GFP-
luciferase-expressing cells were then infected with lentiviral particles codifying for scrambled
or specific shRNA human Stx1a sequences (SMARTchoice Lentiviral Human shRNA particles
were purchased from Dharmacon: Stx1a-Sh01: TCCGACATGACCTCCACAA; Stx1a-Sh02:
TACTCGATCCTGTCAATCA). An independent population of U373 GFP-luciferase cells was in-
fected with retroviral particles codifying for the H3TM domain of Stx1a. To this end, the se-
quence of the rat Stx1a H3TM domain fused with EGFP was subcloned into pBabe puro vector
(a gift from R. Gomis, IRB Barcelona) and retroviral particles were prepared. The resulting cell
populations showed similar levels of luciferase activity compared to their
corresponding controls.
Western blot
Subconfluent cultured cells were lysed with lysis buffer (10mM Tris, pH 7, 500mM NaCl, 1mM
EDTA, 1mM EGTA, 1% Triton X-100, 0.5% NP-40) supplemented with Complete Protease In-
hibitor Cocktail (Roche) and the protein extract was fractioned by SDS-PAGE. Stx1 WB was
performed as previously described [7]. Primary antibodies used for the immunoblot detection
were mAbMunc18a (BD, Biosciences), mAb HPC1 (Sigma) for Stx1, rabbit anti-Stx2 (Synaptic
Systems), mAb anti-Stx3, clone 1–146 (Merck Millipore), rabbit anti-Stx4 (Synatpic Systems),
rabbit anti-Vamp2 (Synaptic Systems), mAb SMI-81 (Sternberger Meyer) for SNAP25, mAb
1501 (Merck Millipore) for actin, and mAb D66 (Sigma) for tubulin. Appropriate secondary
antibodies were obtained from DAKO.
In vitro cell invasion assay
20 x 105 cells were cultured in DB BioCoat Matrigel Invasion Chambers (BD Biosciences) in
DMEM 0.5% FBS. In the lower chamber DMEM 10% FBS was added. After 24 h of incubation
cells were fixed with 4% paraformaldehyde (PFA) in PBS and non-invasive cells were removed
with a cotton swab. Cell nuclei were stained with DAPI and images were collected with a
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fluorescence microscope. Cell counting was done by using ImageJ software (NIH). Cell inva-
sion assays were performed in triplicate a minimum of three times.
Brain tumor xenografts
All mouse experiments were approved and performed in accordance with the guidelines of the
Institutional Animal Care Committee of the Vall d'Hebron Research Institute in agreement
with the European Union and national directives. 1 x 106 cells were stereotactically inoculated
into the corpus striatum of the right brain hemisphere (1 mm anterior and 1.8 mm lateral to
the bregma; 2.5 mm intraparenchymal) of 9-week-old athymic Nude-Foxn1nu mice (Charles
River Laboratories). Cells inoculated in the presence of BoNT/C1 (generously provided by
M.R. Popoff, Institut Pasteur, Paris, France) were pretreated with the toxin (375 pg of toxin)
10 minutes before inoculation and then co-injected. Eight mice per experimental condition
were used. Mice were euthanized when they presented neurological symptoms or a significant
weight loss. In order to estimate the size of tumors the luciferase activity of inoculated tumor
cells was quantified in a Xenogen-CCD camera from IVIS. Magnetic resonance imaging (MRI)
analysis was performed and images were acquired using 9.4 T vertical bore magnet interfaced
to an AVANCE 400 system (Bruker). Under anesthesia by xylazine/ketamine, mice were given
an intraperitoneal injection of gadolinium diethylenetriamine penta-acetic acid at a dose of
0.25 mmol gadolinium/kg body weight and placed in the radio frequency coil (inner diameter
35 mm). After localizer imaging on three orthogonal axes, T1-weighted images of the entire
mouse brain were acquired using a spin echo sequence with TR and TE set to 800 and 5.7 ms,
respectively. Tumor size was quantified by measuring the number of pixels corresponding to
tumor tissue in each image using the software provided by the manufacturer (Bruker). When
the tumor was visible in more than one image, areas corresponding to tumor tissue were
measured together.
BrdU incorporation analysis
For in vitro analysis unsynchronized cultures with an equivalent number of cells were incubat-
ed in media supplemented with 0.05 mM of BrdU during 90 min at 37°C. Then, cells were
fixed with PFA 4% 10 min at room temperature and processed for the immunodetection of
BrdU (see below). All in vitro BrdU incorporation analysis were done in triplicate a minimun
of three times. For in vivo analysis, a single dose of BrdU (100 mg/Kg in PBS) was intraperito-
neally injected to the animals 1 hour prior to their perfusion. Mice were perfused with 4% PFA
in PBS. The brains were dissected out, post-fixed in 4% PFA, cryoprotected in 30% sucrose,
and frozen in cold methyl-butanol. BrdU and GFP double-immunostaining was performed in
40 μm serial cryosections of at least three animals per condition. For immunostaining, the
BrdU antigen was exposed by incubating the sections in 1N HCl at 45°C for 30 min. A rat anti-
BrdU (AbD Serotec) and a rabbit anti-GFP (Invitrogen) were used as primary antibodies. Sec-
tions were immunoreacted for 48h at 4°C, and then incubated with secondary antibodies for
2 hours at room temperature. After washing, sections were mounted with Mowiol. Confocal
images were acquired and the counting of BrdU- and GFP-positive cells was performed using
ImageJ software (NIH).
Cell cycle flow cytometry analysis and double nucleated cell
quantification
Non synchronized cell cultures were individualized by trypsinization and fixed with cold 70%
EtOH. Cell DNA was stained with a 40 ug/ml propidium iodide—100 ug/ml RNAse solution
and cell cycle profiles were obtained by the Scientific technique services of the University of
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Barcelona. For the determination of the proportion of binucleated cells, an equivalent number
of cells were seeded on coverslips and after 24 h they were stained with and anti-tubulin anti-
body and Dapi (Sigma). Conventional epifluorescence images were obtained acquired and the
counting of binucleated cells was performed using ImageJ software (NIH).
Statistics
Statistical analyses were performed using the GraphPad Prism 5.03 software. Student’s
T-test was used to compare means in the in vitro assays. Mann-Whitney test was used for
experiments with animals. Data in graphs are expressed as mean +/- SEM. In graphics one
star means a p value< 0.05, two stars means a p value< 0.01 and three stars a p value
< 0.001.
Results and Discussion
Impairment of Stx1 function reduces proliferation and invasion capacity
of GBM cells in vitro
We first determined the expression of SNARE proteins in various GBM cell lines. Consistent
with previous reports [12], the expression of several SNAREs was detected in GBM cell popula-
tions, including Stx1, Stx4, Vamp2, SNAP25, SNAP23, and of the regulatory protein Munc18
(Fig. 1A). As shown in Fig. 1A, GBM cell populations express different Stx1 isoforms. The
function of all the Stx1 isoforms can be blocked by the action of a dominant negative form con-
sisting of the H3TM (H3: SNARE, TM: transmembrane) domains of Stx1a (Stx1-DN) [7]. The
overexpression of the Stx1-DN form in two GBM cells (U373 and U87) that show a distinct
pattern of Stx1 isoforms expression reduced statistically significant the rate of BrdU incorpo-
ration. (Fig. 1B). Anti- active Caspase3 staining did not reveal any induction of apoptosis (data
not shown). We selected U373 cells for further experimental manipulation. After inoculation
in brains of immunocompromised mice these cells develop invasive tumors that resemble
those observed in patients. We generated stable U373 cell lines (expressing a GFP-Luciferase
fusion protein, GFP-Luc) with down-regulation of Stx1a by using lentiviral vectors (Stx1a-Sh)
(Fig. 1C). We also established a U373 cell line expressing the Stx1a dominant negative form
(U373 Stx1-DN) [7,13]. The blockade of Stx1 did not produce major modifications on the ex-
pression levels of other related syntaxins as Stx2 and Stx3 (Fig. 1C). Then, we determined the
impact of Stx1 inactivation on the properties of U373 cells in vitro. As previously observed, the
stable blockade of Stx1 function reduced approximately between 32 to 43% the rate of BrdU in-
corporation in U373 cells (Fig. 1D). Flow cytometry analysis of cell cycle revealed that the cell
populations with their Stx1 function blocked show a higher proportion of cells (approx. 19–
42%) in G2/M than their corresponding control cells (Fig. 1E). This observation is compatible
with previously published data indicating that the action of several SNARE proteins, particular-
ly Stx1 in some invertebrates and Stx2 and Stx16 in mammalian cells, is important in cytokine-
sis [14,15]. Consistent with this scenario, we observed a higher proportion (40–70%) of
binucleated cells when Stx1 function was blocked (Fig. 1F). In addition, the blockade of Stx1
markedly reduced the migration capacity of U373 cells as tested in Boyden chambers, com-
pared to control cells (Fig. 1G). These findings are consistent with previous data showing that
the down-regulation of Vamp3, Stx13 and Snap23 reduces cell invasion of HT-1080 fibrosarco-
ma cells in vitro, and they support a relevant role of SNARE proteins in tumor cell migration
[16]. Altogether, these results indicate that the disruption of Stx1 function impairs several pro-
cesses in glioblastoma cells.
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Fig 1. Blockade of Stx1 function reduces GBM cell proliferation in vitro. A. Expression of exocytic SNAREmachinery in several established GBM cell
lines determined by immunoblot.B.Quantification of BrdU-positive nuclei in GBM cells. The transient expression of a GFP fused Stx1 dominant negative
form (Stx1-DN) reduces the rate of BrdU incorporation in GBM cells (** p 0.01). Figure shows representative results of three independent experiments. C.
U373 GBM cells with a reduced expression of Stx1 were established by ShRNA lentiviral transduction strategies. Immunoblot showing Stx1 downregulation
in U373 cell populations stably expressing two Stx1a ShRNA (Sh01 and Sh02) sequences. Stx2 and Stx3 expression levels are not modified in U373 cells
Blockade of Stx1 Inhibits Glioblastoma Growth
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Impairment of the Stx1 function results in the reduction of GBM tumor
size in vivo
To study whether Stx1 loss-of-function affects the progression of GBM in vivo, we performed
intracerebral xenotransplantation experiments using U373 GFP-Luc cell lines [17] and quanti-
fied the rate of tumoral growth over time by detecting luciferase activity. Tumors derived from
control U373 cells exhibited a moderate growth until 30 days post-inoculation (30DPI) fol-
lowed by an exponential growth that reached a maximum at 40DPI (Fig. 2A-F). In contrast, tu-
mors derived from U373 Stx1a-Sh01 and U373 Stx1-DN cells showed a dramatic reduction in
size at 40DPI, being 3–7 times smaller than control tumors (Fig. 2A-F).
To confirm these findings, we monitored U373 cell xenografts by means of magnetic reso-
nance imaging (MRI). We confirmed that U373 Stx1a-Sh01 cells formed smaller tumors than
controls (Fig. 2G,H), while U373 Stx1-DN tumors were practically undetectable (data not
shown). Altogether, these results show that distinct Stx1 loss-of-function approaches consis-
tently lead to a dramatic reduction in the progression of experimental GBM in vivo. To deter-
mine whether Stx1 loss-of-function alters proliferation in vivo as previously seen in vitro, nude
mice, grafted with U373 Stx1a-Sh01 and U373 Stx1-DN cells for 30 days, were injected with
BrdU one hour before euthanasia and their brains processed for BrdU-immunohistochemistry.
Quantification of GFP/BrdU-labeled U373 cells revealed a*40–70% reduction in the percent-
age of BrdU+ U373 Stx1a-Sh01 and Stx1-DN cells compared to U373 control cells (Fig. 2I,J).
Our results suggest a scenario where it may be possible to impair the growth of glioblastoma
tumors by using drugs which block Stx1 activity. Botulinum neurotoxins (BoNTs) are potent
and specific inhibitors of SNARE functions. This action is achieved by cleaving and inactivat-
ing selective SNARE proteins [18]. Given their specificity and long-life action, BoNTs are wide-
ly used in medical practice [19]. To examine whether BoNTs can also reduce glioblastoma
tumoral progression, we co-injected U373 cells with BoNT/C1, which cleaves Stx1 [20]. After
40DPI, U373 cell tumors were about five times smaller in mice inoculated with BoNT/C1 than
in untreated, control mice (Fig. 3A,B). In addition to Stx1, Stx2 and Stx3 are targets of BoNT/
C1 [20]. Since all of these syntaxins are expressed in U373 cells (Fig. 1C), it remains to be eluci-
dated whether the effect of BoNT/C1 on U373 GBM growth is due exclusively to its action on
Stx1. Nevertheless, this result supports the feasibility of using Stx1 blocking drugs as therapeu-
tic agents to treat GBMs.
In summary, we show here that the blockade of the SNARE protein Stx1 through three dif-
ferent approaches, including knock-down of Stx1a, expression of the H3TM dominant negative
form of Stx1a and inhibition of Stx1 by treatment with BoNT/C1, consistently results in a dra-
matic decrease in glioblastoma tumor progression in an orthotopic mouse model. This reduc-
tion ranged from 3 times (in Stx1a-Sh01 cells) to 7 times in the experiments with U373 cells
expressing the H3TM construct. To our knowledge, this study is the first to describe that the
inactivation of SNARE proteins has an important impact on the growth of glioblastoma tu-
mors. Our data show that Stx1 loss-of-function results in a decrease in the proliferation of
GBM tumoral cells. However, as SNARE proteins, and particularly Stx1, are involved in many
with their Stx1 function blocked (U373 Stx1a-Sh01/Sh02 and Stx1-DN). D.Quantification of BrdU incorporation in U373 GBM cells. Cells with their Stx1
function stably blocked showed a minor rate of BrdU incorporation (* p 0.05; ** p 0.01). Figure shows representative results of three independent
experiments. E. Cell cycle profile of unsynchronized U373 GBM cells obtained by flow cytometry. The stable blockade of Stx1 function results in an increment
of cell populations at G2/M. F.Quantification of the frequency of binucleated U373 GBM cells. Cells with their Stx1 function stably blocked show a major
proportion of binucleated cells than their respective controls.G. Boyden chamber invasion assay of the indicated U373 cells, showing that loss-of-function of
Stx1 reduces U373 cell invasion capacity (** p 0.01; *** p 0.001). Figure shows representative results of three independent experiments.
doi:10.1371/journal.pone.0119707.g001
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Fig 2. Disruption of the Stx1 function impairs GBM tumor progression in vivo. An equal number of the indicated U373 cell populations were
stereotactically inoculated into the brain of athymic nude mice. The size of the tumors was estimated at different days post-inoculation by the quantification of
luciferase activity in the tumor cells.A, D. Representative images of the luciferase signal frommice inoculated with the indicated U373 GBM cells after 40
DPI. B, E.Growth curves of the indicated U373 GBM tumors showing a marked reduction of the tumor sizes after impairment of Stx1 function (* p 0.05 at
40 DPI). C, F. Scatter plots showing the individual size of the indicated U373 GBM tumors after 40 DPI.G. Representative entire brain NMR images of mice
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other key functions, including migration, exocytosis, protein secretion and adhesion, in addi-
tion to cell proliferation, it is likely that targeting a single SNARE protein may simultaneously
dysregulate several of the above processes, all of them crucial for tumor progression [21,22,23].
Consistent with this idea, we have shown here that the blockage of Stx1 also affects GBM cells
invasion in vitro (Fig. 1G).
Our findings in experimental GBM in vivomodel open up the possibility of using Stx1 or
other SNAREs as potential therapeutic targets. However, in order to be of clinical interest, our
data should be replicated in other GBMmodels. It is interesting to note that BoNTs, the most
potent and selective inhibitors of SNARE proteins, are extensively used in medical practice,
particularly to treat acute pain, muscular spasms, and Parkinson’s disease [19]. Moreover, re-
cent studies report the shrinkage of prostatic and gastric tumors after the injection of BoNT/A
[24,25]. The main drawback associated with a treatment based on the use of inhibitors of
SNARE proteins is toxicity, since neurotransmission can be seriously affected. However, this
problem could be overcome by employing specific peptides which just inhibit the formation of
the SNARE complexes vital for the progression of glioblastomas, but not those involved in
other cellular functions. It is known that differences in the combination/configuration of
SNARE protein complexes explain the diversity of exocytic processes [26]. Thus, it may be pos-
sible to block Stx1 actions on GBM progression without the secondary toxic effects caused by
an inhibition of neurosecretion. Even though future research is clearly required to identify Stx1
loss of function mechanism of action, our data supports the hypothesis that targeting SNARE
proteins may be an effective tool to reduce GBM tumor growth in vivo, by simultaneously tar-
geting several cellular processes relevant to cancer growth and progression.
inoculated with the indicated U373 cell populations after 30 DPI (arrowheads indicate the tumors formed) showing a marked reduction in the Stx1a-Sh01 and
Stx1-DN cells.H. Scatter plot showing the area of the indicated U373 GBM tumors formed after 30 DPI. I. Representative confocal images from histological
sections of 30 DPI brain tumors stained with anti-GFP and anti-BrdU antibodies. J.Quantification of BrdU-positive nuclei in 30 DPI U373 cell tumors showing
that Stx1 loss-of-function reduces proliferation (* p 0.05; *** p 0.001).
doi:10.1371/journal.pone.0119707.g002
Fig 3. Botulinum toxin C1 impairs glioblastoma progression in vivo. A, B. U373 cells were inoculated
into the brain of nude mice in the absence or in the presence of botulinum toxin C1 (BoNT/C1), which
specifically cleaves the SNARE proteins Stx1a/b and SNAP25. (A)Growth curve of GBM tumors determined
by luciferase quantification (* p 0.05 at 40 DPI), and (B) scatter plot showing the individual size of the U373
GBM tumors formed after 40 DPI, demonstrating a marked reduction of GBM after BoNT/C1 treatment.
doi:10.1371/journal.pone.0119707.g003
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